From recent awards, new partnerships, and scientific publications to press releases and new content about the future of diagnostics and monitoring of neurocognitive disorders
Digital biomarker predicts mild cognitive impairment conversion to Alzheimer’s Homepage >> News >> Digital biomarker predicts mild cognitive impairment conversion to Alzheimer’s Digital biomarker
It has been a privilege for ViewMind Inc. to have been a part of the CDLWisconsin, CDL, creative destruction lab
ViewMind Inc. were honored today to keynote at the in person Health 2.0 Conference on the topic of ‘Digital Biomarkers
The project aims to clinically validate ViewMind’s technology to study neurocognitive deficiencies in Long COVID patients.
ViewMind Inc.’s CEO, Mark Edwards, is interviewed by the Silicon Review.
R3i Ventures, provider of successful start-ups Homepage >> News >> R3i Ventures, provider of successful start-ups Click to read the news Related Posts
ViewMind Inc. is honored to be recognized by Business Worldwide in their ’20 Most Innovative Companies to Watch Awards 2021′
ViewMind announces developer agreement with HP to help revolutionise the diagnosis and treatment of cognitive disorders Homepage >> News >> ViewMind announces developer agreement
ViewMind and HP strike deal over cognitive disorders screening Homepage >> News >> ViewMind and HP strike deal over cognitive disorders screening Click to
Brain Health for Life
Easy to perform. Non-invasive.
Precision Neurology.
